ACM
BLFS icon

AlphaCrest Capital Management’s BioLife Solutions BLFS Stock Holding History

AlphaCrest Capital Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,289
Closed -$831K – 1251
2021
Q4 		$831K Buy
22,289
+9,989
+81% +$429K 0.03% 882
2021
Q3 		$521K Buy
+12,300
New +$592K 0.03% 893

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AlphaCrest Capital Management's BLFS Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of BioLife Solutions (BLFS) in Q1 2022, closing a stake of 22,289 shares — an estimated $831K sold.

AlphaCrest Capital Management first reported a position in BLFS in Q3 2021 and held it in 2 quarters. The position peaked at $831K in Q4 2021. 164 funds tracked by Wall St. Rank hold BLFS as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining BioLife Solutions position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 22,289 BioLife Solutions shares in Q1 2022, an estimated $831K.
  • AlphaCrest Capital Management first reported a position in BioLife Solutions in Q3 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's BioLife Solutions position peaked at $831K in Q4 2021.
  • 164 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.